5-Bromo-3-nitro-2-pyridinol

We are 5-Bromo-3-nitro-2-pyridinol CAS:15862-34-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   5-Bromo-3-nitro-2-pyridinol
CAS.NO:15862-34-7
Synonyms:    5-Bromo-3-nitro-2-pyridinol
5-bromo-3-nitro-1H-pyridin-2-one
2(1H)-Pyridinone, 5-bromo-3-nitro-
5-Bromo-3-nitropyridin-2-ol
5-BroMo-2-hydroxy-3-nitropyridine
 
Molecular Formula:C5H3BrN2O3
Molecular Weight:218.99300
 
Physical and Chemical Properties:
Density:1.98 g/cm3
Boiling point:296.7ºC at 760 mmHg
Melting point:246-250 °C
Flash point:133.2ºC
Index of Refraction:1.647
 
Specification:
Appearance:White to brown powder
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:Preserve in well-closed, light-resistant and airtight containers
Application: Pesticide intermediates, dye intermediates, flavor and fragrance intermediates, pharmaceutical intermediates

5-Bromo-3-nitro-2-pyridinol


Related News: “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”9-(3-bromophenyl)carbazole CAS:185112-61-2 Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.(S) -1-fenil-1,2,3,4-tetrahidroisoquinolina CAS:118864-75-8 The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.3- (4-clorobutil) -1H-indol-5-carbonitrilo CAS:143612-79-7 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.

Related Products
Product Name
2′-deoxyadenosine View Details
Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate View Details
5,7-Dihydro-2-methylthieno[3,4-d]pyrimidine View Details
1-[(2-Bromophenyl)sulfanyl]-2,4-dimethylbenzene manufacturer 2-Methylpyrazine manufacturer 2-Ethoxythiazole manufacturer 6-Fluoro-2-methyl-1H-indole manufacturer 4-(4-chlorobutyl)pyridine,hydrochloride manufacturer